Administration of tumor CSV-targeted IL-12 (ttIL-12), a fusion gene that encodes IL-12 and a comprehensive CSV-targeting carcinoma homing peptide, increased tumor accumulation of IL-12 in vivo [19], and ttIL-12 therapy via intramuscular electroporation promoted the inhibition of tumor growth with less liver toxicity than wild-type IL-12 (wtIL-12) therapy [19]. Here, SPRR2A is linked to carcinoma.